ImmunityBio, Inc.
Clinical trials sponsored by ImmunityBio, Inc., explained in plain language.
Immunotherapy biotech developing cancer treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immune booster plus standard therapy shows promise for bladder cancer Results expected Sep 2026 (estimated)
- Could an immune booster beat long COVID? small trial begins Results expected Oct 2026 (estimated)
- New bladder cancer cocktail aims to spare patients from surgery Results expected Nov 2026 (estimated)
- Immune cell cocktail takes on Platinum-Resistant ovarian cancer Results expected May 2027 (estimated)
- New immune-boosting combo targets stubborn lymphoma Results expected May 2027 (estimated)
-
New immune cell therapy targets Hard-to-Treat leukemia in early trial
Disease control Stopped earlyThis early-phase trial tests a new treatment called CD19 t-hANK for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back after previous treatments. The therapy uses specially designed immune cells to attack cancer cells. Up to 10 participant…
Phase 1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Lung cancer drug combo trial halted midway – what we know
Disease control Stopped earlyThis study tested a new drug called nogapendekin alfa inbakicept combined with standard treatments for people with advanced or metastatic non-small cell lung cancer. The trial was stopped early, so results are limited. It involved 102 adults who had not received prior chemotherap…
Phase 3 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC